| Symbol | ENGN |
|---|---|
| Name | ENGENE HOLDINGS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 4868 RUE LEVY,SUITE 220, SAINT-LAURENT, Quebec, H4R 2P1, Canada |
| Telephone | +1 514 - 332-4888 |
| Fax | — |
| — | |
| Website | https://www.engene.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001980845 |
| Description | enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Companys proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Companys DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium. Additional info from NASDAQ: |
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
Read moreNew Form 3 - enGene Therapeutics Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0000929638-26-002666 <b>Size:</b> 13 KB
Read moreNew Form 3 - enGene Therapeutics Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0000929638-26-002667 <b>Size:</b> 9 KB
Read moreenGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Read more(90% Positive) ENGENE HOLDINGS INC. (ENGNW) Provides Update on plan for situ (CIS)
Read moreenGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Read moreAstley-Sparke Philip 🟢 acquired 31.0K shares (1 derivative) of enGene Therapeutics Inc. (ENGN) at $1.75 Transaction Date: Jun 16, 2026 | Filing ID: 002263
Read moreBRUNK GERALD A 🟢 acquired 31.0K shares (1 derivative) of enGene Therapeutics Inc. (ENGN) at $1.75 Transaction Date: Jun 16, 2026 | Filing ID: 002262
Read moreGlickman Richard M 🟢 acquired 31.0K shares (1 derivative) of enGene Therapeutics Inc. (ENGN) at $1.75 Transaction Date: Jun 16, 2026 | Filing ID: 002261
Read moreGrossman William 🟢 acquired 231.0K shares (2 derivative) of enGene Therapeutics Inc. (ENGN) at $1.75 Transaction Date: Jun 16, 2026 | Filing ID: 002260
Read more